Thrilled to announce our meta-analysis and systematic review on myeloid sarcoma is now published in @Cancers_MDPI !
Check out our clinically relevant results here: https://t.co/yM624ajzN7
#leukemia#myeloidsarcoma#CancerResearch
Excited to share our new 📃 on myeloid sarcoma (MS), where we found frequent (56%) NGS discordance between bone marrow and MS tissue and exclusive presence of NPM1 mutations in MS- which should be checked routinely and targeted! @jeffMDMBA@malignantheme
https://t.co/FKcvtIcdOQ
Excited to share our latest findings! Join us this evening at Poster 2768 as @sandhyadhiman5 presents on menin interaction and nuclear export inhibition in NPM1-mutant AML.#ASH24@ASH_hematology
Check out our interesting case report of pancytopenia post mild COVID recovery, featured as the cover story of Hematology Reports Vol. 16, Issue 1 @malignantheme@OpsBug
🌟🌟Two cases of new-onset PNH/aplastic anemia syndrome and aplastic anemia associated with COVID-19, but but the exact mechanism is still unknown.
🔗https://t.co/m7sf8LK7U8
👨🔬 By Dr. Suresh Balasubramanian
@MDPIOpenAccess
What a wonderful story put together by Dr.Kubota! Congrats to Dr. Maciejewski’s Lab @ClevelandClinic Molecular and clinical analyses of PHF6 mutant myeloid neoplasia provide their pathogenesis and therapeutic targeting | @NatureComms https://t.co/4X0JWR7uMC
In a talk @BrownMedicine, Editor-in-Chief @zakkohane, urged doctors-in-training to understand and make use of artificial intelligence.
“It's an existential opportunity and threat to medicine to not take [AI] seriously.”
See what else he said: https://t.co/UHX9pTOnLU
Does NPM1 MT convey similar impact when in De Novo vs T/sAML? 👇✅ your 🗓️ for this session that begins at 245PM today! #ASH23@OpsBug@jeffMDMBA@NanjaSushmitha @LakshmiBPotluri
Our #ASH23 poster on meta-analysis of myeloid sarcoma, #3811, in 900s section. One of the largest cohorts of myeloid sarcoma, pooled to gain insights on the disease!
Cc: @DakshinPadman#ASHKudos to mentor and PI @malignantheme
https://t.co/ZGC4mPwd4S
#ASHKudos to this morning’s presentations in Emerging Tools, Techniques and AI in Hematology. Exciting to learn more about machine learning and computational models under development #ASH23
Epigenetic aging and age acceleration can be potential biomarkers for targeted therapy in AML. More interesting data being shared by @OpsBug@jeffMDMBA#ASH23